(Q36081993)

12 August 2017

1 reference

title

Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics (English)

1 reference

12 August 2017

anti-retroviral agent

0 references

3

Simon Mallal

1 reference

12 August 2017

2

Peter Reiss

1 reference

12 August 2017

David Nolan

1

1 reference

PubMed ID

15794714

12 August 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

Expert Opinion on Drug Safety

12 August 2017

1 reference

12 August 2017

4

1 reference

12 August 2017

2

1 reference

12 August 2017

201-218

1 reference

Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Switching effective antiretroviral therapy: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Lipodystrophy in patients naive to HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Ultrastructural features of highly active antiretroviral therapy-associated partial lipodystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6-12 months of commencing nucleoside reverse transcriptase inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Quantitation of blood lymphocyte mitochondrial DNA for the monitoring of antiretroviral drug-induced mitochondrial DNA depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Renal safety of tenofovir in HIV treatment-experienced patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Reasons for Early Abacavir Discontinuation in HIV-Infected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Increasing prevalence of the metabolic syndrome among u.s. Adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Lifestyle behaviors associated with lower risk of having the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Risk factors for the metabolic syndrome: the Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Epidemiology and treatment of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Impact of HIV infection and HAART on serum lipids in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Apoprotein c-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen: a stable isotope kinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Hypertriglyceridemia in the acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Combination antiretroviral therapy and the risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.2.201

21 January 2018

Identifiers

DOI

10.1517/14740338.4.2.201

1 reference

12 August 2017

1 reference

PubMed ID

15794714